Onabotulinum toxin a treatment for posttraumatic trigeminal neuropathic pain: case series and literature review

This case series aimed to assess the treatment outcomes of onabotulinum toxin A (BTX-A) in patients with refractory posttraumatic trigeminal neuropathic pain (PTNP) and to conduct a narrative review of the evidence for BTX-A in PTNP. Thirteen patients were treated with BTX-A infiltrations. Patient demographic and pain characteristics, BTX-A administration, and treatment outcomes were retrospectively analyzed. Papers retrieved after a literature search of articles on PTNP treatment using BTX-A were reviewed. Six patients reported an improvement in pain 3 months after the initial BTX-A injection, with 4 patients reporting a 50% reduction. Two patients achieved an 80% reduction in pain score over 3 years of BTX-A therapy. Three patients reported temporary ipsilateral facial muscle weakness. The literature review revealed five case reports on the use of BTX-A in PTNP patients that reported similar effectiveness to the present cohort study. BTX-A may be a potential treatment modality for refractory PTNP, thus reducing the need for polypharmacy. Multiple intraoral BTX-A injections administered over the painful sites are well tolerated, safe and easily practiced. High-quality studies are required to evaluate the long-term therapeutic efficacy and side effects of BTX-A therapy.

Botulinum toxin; Neuropathic pain; Submucosal; Traumatic trigeminal neuropathy; Trigeminal neuropathy

[1] International classification of orofacial pain, 1st edition (ICOP). Cephalalgia. 2020; 40: 129–221.

[2] Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia 2018; 38: 1–211.

[3] Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016; 157: 1599–1606.

[4] International Association for the Study of Pain Special Interest Group. Neuropathic pain (NeuPSIG). 2021. Available at: https://www.iasp-pain.org/group/neuropathic-pain-neupsig/ (Accessed: 16 February 2023).

[5] Klazen Y, Van der Cruyssen F, Vranckx M, Van Vlierberghe M, Politis C, Renton T, et al. Iatrogenic trigeminal post-traumatic neuropathy: a retrospective two-year cohort study. International Journal of Oral and Maxillofacial Surgery. 2018; 47: 789–793.

[6] McArdle LW, Renton T. The effects of NICE guidelines on the management of third molar teeth. British Dental Journal. 2012; 213: E8–E8.

[7] Renton T. Prevention of iatrogenic inferior alveolar nerve injuries in relation to dental procedures. Dental Update. 2010; 37: 350–363.

[8] Renton T, Yilmaz Z, Gaballah K. Evaluation of trigeminal nerve injuries in relation to third molar surgery in a prospective patient cohort. Recommendations for prevention. International Journal of Oral and Maxillofacial Surgery. 2012; 41: 1509–1518.

[9] Renton T. Trigeminal nerve injuries. Australian Endodontic Journal. 2018; 44: 159–169.

[10] Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: facts and fiction. Cephalalgia. 2017; 37: 670–679.

[11] Renton T, Yilmaz Z. Profiling of patients presenting with post traumatic neuropathy of the trigeminal nerve. Journal of Orofacial Pain. 2011; 25: 333–344.

[12] Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008; 136: 380–387.

[13] Haroutounian S, Jensen TS. Neuropathic pain following surgery. Nerves and Nerve Injuries. 2015; 112: 113–127.

[14] Van der Cruyssen F, Peeters F, Gill T, De Laat A, Jacobs R, Politis C, et al. Signs and symptoms, quality of life and psychosocial data in 1331 post-traumatic trigeminal neuropathy patients seen in two tertiary referral centres in two countries. Journal of Oral Rehabilitation. 2020; 47: 1212–1221.

[15] Smith JG, Elias LA, Yilmaz Z, Barker S, Shah K, Shah S, et al. The psychosocial and affective burden of posttraumatic neuropathy following injuries to the trigeminal nerve. Journal of Orofacial Pain. 2013; 27: 293–303.

[16] Perrot S, Lantéri‐Minet M. Patients’ global impression of change in the management of peripheral neuropathic pain: clinical relevance and correlations in daily practice. European Journal of Pain. 2019; 23: 1117–1128.

[17] Finnerup NB, Attal N, Haroutounian S. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Journal of Vascular Surgery. 2015; 62: 1091.

[18] Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology. 2010; 17: 1113.

[19] Schlereth T. Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology. Neurological Research and Practice. 2020; 2: 16.

[20] Bates D, Schultheis BC, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, et al. A comprehensive algorithm for management of neuropathic pain. Pain Medicine. 2019; 20: S2–S12.

[21] National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings. 2020. Available at: https://www.nice.org.uk/guidance/cg173 (Accessed: 16 February 2023).

[22] Benoliel R, Kahn J, Eliav E. Peripheral painful traumatic trigeminal neuropathies. Oral Diseases. 2012; 18: 317–332.

[23] Yeh YC, Cappelleri JC, Marston XL, Shelbaya A. Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: a MarketScan database study. PLOS ONE. 2021; 16: e0242467.

[24] Liu W-, Kanungo A, Toth C. Equivalency of tricyclic antidepressants in open-label neuropathic pain study. Acta Neurologica Scandinavica. 2014; 129: 132–141.

[25] Park HJ, Lee Y, Lee J, Park C, Moon DE. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Canadian Journal of Anesthesia. 2006; 53: 470–477.

[26] Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins. 2017; 9: 260.

[27] Mittal SO, Safarpour D, Jabbari B. Botulinum toxin treatment of neuropathic pain. Seminars in Neurology. 2016; 36: 73–83.

[28] Bohluli B, Motamedi MHK, Bagheri SC, Bayat M, Lassemi E, Navi F, et al. Use of botulinum toxin a for drug-refractory trigeminal neuralgia: preliminary report. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2011; 111: 47–50.

[29] Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomised, double-blind, placebo-controlled trial. Cephalalgia. 2012; 32: 443–450.

[30] Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Medicine. 2010; 11: 1827–1833.

[31] Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia. The Clinical Journal of Pain. 2013; 29: 857–864.

[32] Han ZA, Song DH, Oh HM, Chung ME. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Annals of Neurology. 2016; 79: 569–578.

[33] Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Annals of Neurology. 2008; 64: 274–283.

[34] Layeeque R, Hochberg J, Siegel E, Kunkel K, Kepple J, Henry-Tillman RS, et al. Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Annals of Surgery. 2004; 240: 608–614.

[35] Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain. Neurology. 2009; 72: 1473–1478.

[36] Ghasemi M, Ansari M, Basiri K, Shaigannejad V. The effects of intradermal botulinum toxin type A injections on pain symptoms of patients with diabetic neuropathy. Journal of Research in Medical Sciences. 2014; 19: 106–111.

[37] Kuriyama A. Botulinum toxin a for prophylactic treatment of migraine and tension headaches in adults. JAMA. 2012; 307: 1736.

[38] Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The Journal of Headache and Pain. 2018; 19: 13.

[39] Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomised, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793–803.

[40] Durham PL, Cady R. Insights into the mechanism of OnabotulinumtoxinA in chronic migraine. The Journal of Head and Face Pain. 2011; 51: 1573–1577.

[41] Herrero Babiloni A, Kapos FP, Nixdorf DR. Intraoral administration of botulinum toxin for trigeminal neuropathic pain. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2016; 121: e148–e153.

[42] García-Sáez R, Gutiérrez-Viedma Á, González-García N, Gómez-Mayordomo V, Porta-Etessam J, Cuadrado ML. OnabotulinumtoxinA injections for atypical odontalgia: an open-label study on nine patients. Journal of Pain Research. 2018; 11: 1583–1588.

[43] Yoon SH, Merrill RL, Choi JH, Kim ST. Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain Medicine. 2010; 11: 630–632.

[44] Moreno-Hay I, Mishra P, Okeson J. Intraoral administration of botulinum toxin for continuous dentoalveolar neuropathic pain: a case series. Journal of Oral & Facial Pain and Headache. 2019; 33: 160–164.

[45] Cuadrado M, García-Moreno H, Arias J, Pareja JA. Botulinum neurotoxin type-A for the treatment of atypical odontalgia. Pain Medicine. 2016; 17: 1717–1721.

[46] De la Torre Canales G, Poluha RL, Ferreira DM, Stuginski-Barbosa J, Conti PCR. Botulinum toxin-A injections as therapy for chronic painful post-traumatic trigeminal neuropathy: case report. Brazilian Dental Science. 2020; 23: 1–5.

[47] Treede R-, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain. Neurology. 2008; 70: 1630–1635.

[48] Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nature Reviews Disease Primers. 2017; 3: 17002.

[49] Kankowski S, Grothe C, Haastert‐Talini K. Neuropathic pain: spotlighting anatomy, experimental models, mechanisms, and therapeutic aspects. European Journal of Neuroscience. 2021; 54: 4475–4496.

[50] Renton T, Van der Cruyssen F. Diagnosis, pathophysiology, management and future issues of trigeminal surgical nerve injuries. Oral Surgery. 2020; 13: 389–403.

[51] Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitisation. Pain. 2006; 122: 315–325.

[52] Yang KY, Kim MJ, Ju JS, Park SK, Lee CG, Kim ST, et al. Antinociceptive effects of botulinum toxin type A on trigeminal neuropathic pain. Journal of Dental Research. 2016; 95: 1183–1190.

[53] Nathan N, Dieb W, Descroix V, Svensson P, Ernberg M, Boucher Y. Topical review: potential use of botulinum toxin in the management of painful posttraumatic trigeminal neuropathy. Journal of Oral & Facial Pain and Headache. 2017; 31: 7–18.

[54] Clark GT, Stiles A, Lockerman LZ, Gross SG. A critical review of the use of botulinum toxin in orofacial pain disorders. Dental Clinics of North America. 2007; 51: 245–261.

[55] Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. Journal of Cell Science. 2007; 120: 2864–2874.

[56] Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain. 2004; 107: 125–133.

[57] Matak I, Bach-Rojecky L, Filipović B, Lacković Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011; 186: 201–207.

[58] Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins. 2017; 9: 260.

[59] Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. The Journal of Head and Face Pain. 2003; 43: 9–15.

[60] Gharibian D, Polzin JK, Rho JP. Compliance and persistence of antidepressants versus anticonvulsants in patients with neuropathic pain during the first year of therapy. The Clinical Journal of Pain. 2013; 29: 377–381.

[61] Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Medical Journal. 2011; 26: 155–159.

[62] Brown MT, Bussell JK. Medication adherence: who cares? Mayo Clinic Proceedings. 2011; 86: 304–314.

[63] Davies SJC, Jackson PR, Ramsay LE, Ghahramani P. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Archives of Internal Medicine. 2003; 163: 592.

[64] Chiriac AM, Demoly P. Multiple drug hypersensitivity syndrome. Current Opinion in Allergy & Clinical Immunology. 2013; 13: 323–329.

[65] Omer HMRB, Hodson J, Thomas SK, Coleman JJ. Multiple drug intolerance syndrome: a large-scale retrospective study. Drug Safety. 2014; 37: 1037–1045.

[66] Faasse K, Grey A, Horne R, Petrie KJ. High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication. Pharmacoepidemiology and Drug Safety. 2015; 24: 592–599.

[67] Denk F, McMahon SB. Neurobiological basis for pain vulnerability: why me? Pain. 2017; 158: S108–S114.

[68] Renton T. Tooth‐related pain or not? The Journal of Head and Face Pain. 2020; 60: 235–246.

[69] Hansson P. Neuropathic pain: clinical characteristics and diagnostic workup. European Journal of Pain. 2002; 6: 47–50.

[70] Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2016; 15: 555–565.

[71] Bouhassira D, Branders S, Attal N, Fernandes AM, Demolle D, Barbour J, et al. Stratification of patients based on the neuropathic pain symptom inventory: development and validation of a new algorithm. Pain. 2021; 162: 1038–1046.

[72] Hogan Q, Abram S. Neural blockade for diagnosis and prognosis. Anesthesiology. 1997; 86: 216–241.

[73] Durand PD, Couto RA, Isakov R, Yoo DB, Azizzadeh B, Guyuron B, et al. Botulinum toxin and muscle atrophy: a wanted or unwanted effect. Aesthetic Surgery Journal. 2016; 36: 482–487.

[74] Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996; 46: 26–29.

[75] Witmanowski H, Błochowiak K. The whole truth about botulinum toxin—a review. Advances in Dermatology and Allergology. 2020; 37: 853–861.

[76] Salari M, Sharma S, Jog MS. Botulinum toxin induced atrophy: an uncharted territory. Toxins. 2018; 10: 313.

[77] Hristova AH, Joseph LN, Sathe SA, Wade JB. Severe nervous system complications after botulinum type a therapy: three case reports with reviews of FDA-reported nervous system adverse effects. PM & R. 2012; 4: 613–623.

[78] De Laet K, Wyndaele J. Adverse events after botulinum a toxin injection for neurogenic voiding disorders. Spinal Cord. 2005; 43: 397–399.

[79] Jahromi AH and Konofaos P. Contralateral facial Botulinum toxin injection in cases with acute facial paralysis may improve the functional recovery: where we stand and the future direction. World Journal of Plastic Surgery. 2021; 10: 89–92.